Afatinib plus bevacizumab combination after acquired resistance to EGFR tyrosine kinase inhibitors in EGFR -mutant non-small cell lung cancer: Multicenter, single-arm, phase 2 trial (ABC Study)-Reference-Cited by-同舟云学术

Afatinib plus bevacizumab combination after acquired resistance to EGFR tyrosine kinase inhibitors in EGFR -mutant non-small cell lung cancer: Multicenter, single-arm, phase 2 trial (ABC Study)

Published:2018-09-07 Issue:19 Volume:124 Page:3830-3838
ISSN:0008-543X
Container-title:Cancer
language:en
Short-container-title:Cancer

Author:

Hata Akito¹,Katakami Nobuyuki¹,Kaji Reiko¹,Yokoyama Toshihide²,Kaneda Toshihiko²,Tamiya Motohiro³,Inoue Takako³,Kimura Hiromi⁴,Yano Yukihiro⁴,Tamura Daisuke⁵,Morita Satoshi⁶,Negoro Shunichi⁷,the HANSHIN Oncology Group for

Affiliation:

1. Department of Medical Oncology; Kobe City Medical Center General Hospital; Kobe Japan

2. Department of Respiratory Medicine; Kurashiki Central Hospital; Kurashiki Japan

3. Department of Thoracic Oncology; Osaka International Cancer Institute; Osaka Japan

4. Department of Thoracic Oncology; Toneyama National Hospital, National Hospital Organization; Toyonaka Japan

5. Department of Respiratory Medicine; Kobe University Graduate School of Medicine; Kobe Japan

6. Department of Biomedical Statistics and Bioinformatics; Kyoto University Graduate School of Medicine; Kyoto Japan

7. Department of Medical Oncology; Takarazuka City Hospital; Takarazuka Japan

Funder

Boehringer Ingelheim

Publisher

Wiley

Subject

Cancer Research,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1002/cncr.31678/fullpdf

Reference35 articles.

1. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib;Lynch;N Engl J Med,2004

2. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy;Paez;Science,2004

3. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer;Soda;Nature,2007

4. Impact of specific epidermal growth factor receptor (EGFR) mutations and clinical characteristics on outcomes after treatment with EGFR tyrosine kinase inhibitors versus chemotherapy in EGFR-mutant lung cancer: a meta-analysis;Lee;J Clin Oncol,2015

5. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain;Pao;PLoS Medicine,2005

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Additional local therapy before disease progression for EGFR-mutated advanced lung cancer: a systematic review and meta-analysis;Translational Lung Cancer Research;2024-03

2. The efficacy and safety of adding anlotinib in gradual progression on third-generation EGFR-TKIs for EGFR-mutant advanced nonsmall cell lung cancer;Anti-Cancer Drugs;2024-02-23

3. Comparison of osimertinib plus bevacizumab against osimertinib alone in NSCLC harboring EGFR mutations: a systematic review and meta-analysis;Therapeutic Advances in Medical Oncology;2024-01

4. Low‑dose anlotinib combined with EGFR‑TKI can be used as an alternative for EGFR‑TKI‑resistant non‑small cell lung cancer in elderly patients;Oncology Letters;2023-06-13

5. Natural Cyclophilin A Inhibitors Suppress the Growth of Cancer Stem Cells in Non-Small Cell Lung Cancer by Disrupting Crosstalk between CypA/CD147 and EGFR;International Journal of Molecular Sciences;2023-05-29